GlassScriptPhysician profile
Steven M Katz
NPI 1679502140
$18,383.36
in general payments reported to CMS, 2019-2025
32 companies · $3,641 in 2025
The $3,641 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,470 · 2020: $1,566 · 2021: $2,543 · 2022: $2,495 · 2023: $3,251 · 2024: $3,418 · 2025: $3,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $34.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,275.67 |
| Education | $34.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,917.08 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,553.47 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Lundbeck LLC | $1,400.61 | 2019-2025 | Rexulti |
| Corium, LLC | $1,240.38 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $1,148.57 | 2019-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $1,077.18 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,075.84 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,063.24 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,035.81 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $919.13 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $806.73 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $776.09 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $700.21 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $643.31 | 2019-2025 | Trintellix |
| Allergan, INC. | $533.37 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $389.00 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $367.71 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $265.18 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Ironshore Pharmaceuticals INC. | $223.36 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $208.17 | 2022-2024 | Quviviq |
| Vertical Pharmaceuticals, LLC | $194.86 | 2024-2025 | Relexxii, Methylphenidate Hydrochloride |
| Merck Sharp & Dohme LLC | $151.92 | 2020-2023 | Belsomra |
| Orexo US, INC. | $131.68 | 2019-2025 | Zubsolv |
| Adlon Therapeutics L.P. | $128.80 | 2019-2021 | |
| Neos Therapeutics, LP | $111.66 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $97.24 | 2025 | Jornay Pm |
| Jazz Pharmaceuticals INC. | $74.56 | 2019-2021 | |
| Tris Pharma INC | $66.21 | 2023-2025 | Dyanavel Xr |
| Indivior INC. | $34.83 | 2021-2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $16.52 | 2019 | |
| Tms Neurohealth Centers INC. | $15.72 | 2025 | Tms Neurohealth Centers INC. |
| Shire North American Group INC | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.